These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18776253)

  • 1. Physicochemical stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications.
    Maasch C; Buchner K; Eulberg D; Vonhoff S; Klussmann S
    Nucleic Acids Symp Ser (Oxf); 2008; (52):61-2. PubMed ID: 18776253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer(®) therapeutics.
    Vater A; Klussmann S
    Drug Discov Today; 2015 Jan; 20(1):147-55. PubMed ID: 25236655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spiegelmer Inhibition of MCP-1/CCR2--Potential as an Adjunct Immunosuppressive Therapy in Transplantation.
    Kalnins A; Thomas MN; Andrassy M; Müller S; Wagner A; Pratschke S; Rentsch M; Klussmann S; Kauke T; Angele MK; Bazhin AV; Fischereder M; Werner J; Guba M; Andrassy J
    Scand J Immunol; 2015 Aug; 82(2):102-9. PubMed ID: 25970072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
    Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
    J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2.
    Oberthür D; Achenbach J; Gabdulkhakov A; Buchner K; Maasch C; Falke S; Rehders D; Klussmann S; Betzel C
    Nat Commun; 2015 Apr; 6():6923. PubMed ID: 25901662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice.
    Ninichuk V; Clauss S; Kulkarni O; Schmid H; Segerer S; Radomska E; Eulberg D; Buchner K; Selve N; Klussmann S; Anders HJ
    Am J Pathol; 2008 Mar; 172(3):628-37. PubMed ID: 18258851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and testing of aptamers for cancer.
    Barbas AS; White RR
    Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropathy.
    Clauss S; Gross O; Kulkarni O; Avila-Ferrufino A; Radomska E; Segerer S; Eulberg D; Klussmann S; Anders HJ
    J Pathol; 2009 May; 218(1):40-7. PubMed ID: 19156777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA aptamers and spiegelmers: synthesis, purification, and post-synthetic PEG conjugation.
    Hoffmann S; Hoos J; Klussmann S; Vonhoff S
    Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.46.1-30. PubMed ID: 21901672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotechnology and aptamers: applications in drug delivery.
    Levy-Nissenbaum E; Radovic-Moreno AF; Wang AZ; Langer R; Farokhzad OC
    Trends Biotechnol; 2008 Aug; 26(8):442-9. PubMed ID: 18571753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro selection using a dual RNA library that allows primerless selection.
    Jarosch F; Buchner K; Klussmann S
    Nucleic Acids Res; 2006 Jul; 34(12):e86. PubMed ID: 16855281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects.
    Vater A; Klussmann S
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):253-61. PubMed ID: 12669461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleic acid aptamers as adjuncts to vaccine development.
    Becker KC; Becker RC
    Curr Opin Mol Ther; 2006 Apr; 8(2):122-9. PubMed ID: 16610764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class.
    Wlotzka B; Leva S; Eschgfäller B; Burmeister J; Kleinjung F; Kaduk C; Muhn P; Hess-Stumpp H; Klussmann S
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8898-902. PubMed ID: 12070349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Screening and characterization of DNA aptamers with hTNF-alpha binding and neutralizing activity].
    Guo KT; Yan XR; Huang GJ; Xu CX; Chai YS; Zhang ZQ
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):730-3. PubMed ID: 15971588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex target SELEX.
    Shamah SM; Healy JM; Cload ST
    Acc Chem Res; 2008 Jan; 41(1):130-8. PubMed ID: 18193823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aptamers: from bench side research towards patented molecules with therapeutic applications.
    Majumder P; Gomes KN; Ulrich H
    Expert Opin Ther Pat; 2009 Nov; 19(11):1603-13. PubMed ID: 19852719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo.
    Maasch C; Vater A; Buchner K; Purschke WG; Eulberg D; Vonhoff S; Klussmann S
    J Biol Chem; 2010 Dec; 285(51):40012-8. PubMed ID: 20961861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic investigation of optimal aptamer immobilization for protein-microarray applications.
    Walter JG; Kökpinar O; Friehs K; Stahl F; Scheper T
    Anal Chem; 2008 Oct; 80(19):7372-8. PubMed ID: 18729475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemical biology of aptamers.
    Mayer G
    Angew Chem Int Ed Engl; 2009; 48(15):2672-89. PubMed ID: 19319884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.